Share This Page

Ensuring Lecanemab Reaches Those Who Need It

Lecanemab (marketed as Leqembi) is today's top Alzheimer's drug. Why does equitable access to this drug remain a significant challenge? What needs to be done?
ai generated, elderly man, wise, wisdom, character, elderly gentleman, elderly, fashion, elegance

Lecanemab, marketed as Leqembi, has emerged as a promising treatment for Alzheimer’s disease, offering hope to patients and caregivers alike. However, despite its potential, equitable access to this drug remains a significant challenge, with disparities in availability and affordability affecting vulnerable populations.

Below is a chart illustrating the disparities in access to lecanemab (Leqembi) based on location and socioeconomic status.

FactorUrban PatientsRural PatientsWealthier PatientsLower-Income Patients
Likelihood of AccessHighLowHighLow
Availability of Specialized CentersWidely availableLimitedAccessibleLess accessible
Frequency of Infusions & ImagingEasier to manageHarder due to distanceAffordableExpensive, out-of-pocket costs
Insurance Coverage & Financial SupportMore likely to have private insuranceLimited insurance optionsStrong coverageLimited coverage, bureaucratic hurdles
Awareness & EducationHigh due to healthcare outreachLower due to geographic isolationHighLower in underserved communities

This table highlights how urban, wealthier patients have significantly easier access to the drug, while rural and lower-income individuals face numerous barriers.

Barriers to Access

A recent study has highlighted stark disparities in the adoption of lecanemab, revealing that male, urban, and wealthier patients are more likely to receive the treatment. The drug, which costs approximately $26,000 per year—plus an additional $7,000 in ancillary expenses—poses a financial burden for many, particularly those without adequate insurance coverage.

Additionally, the treatment process itself presents hurdles. Patients must undergo extensive testing before becoming eligible, followed by biweekly infusions at specialized centers and periodic imaging scans. These requirements disproportionately affect individuals from lower-income backgrounds and rural areas, where access to specialized healthcare facilities is limited.

The disparity in access to lecanemab (brand name Leqembi) is particularly pronounced among urban and wealthier populations, and several factors contribute to this trend.

Urban vs. Rural Divide

Patients living in urban areas are significantly more likely to receive lecanemab than those in rural regions. A study found that 88% of lecanemab recipients resided in urban areas, compared to only 12% in rural communities. This discrepancy is largely due to the availability of specialized healthcare facilities in cities, where patients can undergo the required biweekly infusions and periodic imaging scans. Rural areas often lack these specialized centers, making it difficult for patients to access the drug.

Additionally, urban residents tend to have greater awareness of new treatments, thanks to better healthcare outreach and education. Rural patients, on the other hand, may struggle with limited transportation options, making frequent visits to infusion centers impractical.

Socioeconomic Barriers

Wealthier individuals are far more likely to receive lecanemab than those from lower-income backgrounds. The drug costs approximately $26,000 per year, with an additional $7,000 in ancillary expenses. While Medicare covers the treatment, many patients still face out-of-pocket costs that can be prohibitive. Those with higher socioeconomic status are 24 times more likely to receive lecanemab than lower-income patients, despite Medicare coverage.

Moreover, wealthier patients are more likely to have private insurance that covers additional costs, as well as access to top-tier medical specialists who can guide them through the complex eligibility process. Lower-income patients, particularly those relying solely on Medicare or Medicaid, often struggle with bureaucratic hurdles that delay or prevent access to the drug.

Policy Implications

Experts argue that these disparities highlight the need for policy intervention to ensure equitable access. Some suggest that Medicare should reassess its coverage of lecanemab, considering its high cost, modest clinical benefits, and significant safety risks. Others advocate for expanded healthcare infrastructure in rural areas and financial assistance programs for lower-income patients.

Without systemic changes, lecanemab risks becoming another breakthrough therapy that remains out of reach for those who need it most. Addressing these inequities is crucial to ensuring that all patients—regardless of location or financial status—can benefit from medical advancements.

To address these inequities, policymakers must focus on improving awareness, expanding healthcare infrastructure, and ensuring financial assistance for underprivileged patients. Without such measures, lecanemab risks becoming another example of a breakthrough therapy that remains out of reach for those who need it most.

Conclusions on Lecanemab

While lecanemab represents a significant advancement in Alzheimer’s treatment, its accessibility remains a pressing issue. Addressing geographic and socioeconomic disparities in healthcare is crucial to ensuring that all patients—regardless of background—can benefit from medical innovations. Without systemic changes, the promise of lecanemab may remain unfulfilled for many.

Related:

Email me when people comment
Notify of
guest

0 Comments
Inline Feedbacks
View all comments
Edited by:
Picture of P. Berger

P. Berger

Caring for dementias such as Alzheimer's among family and friends, Peter committed to help preserve the dignity of people affected by Alzheimer's. AlzheimersWeekly.com is the fruit of that commitment.

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Share this page To

Dementia Books & Videos on Amazon:

More From Alzheimer's Weekly

Disabled gun (Courtesy: Commons.Wikimedia.org)
Care Tips

Guns & Dementia

Elderly Americans are the most likely citizens to own a gun AND the most likely patients to have dementia. How great is the danger? What should be done?

Read More »
Family

A Happy Partner Leads to Less Dementia

Researchers find optimistic people contribute to the health of their partners, staving off risk factors leading to Alzheimer’s disease, other dementias and cognitive decline as they grow old together.

Read More »
Share to Facebook
Twitter
LinkedIn

This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chafe, the important articles & videos from each week’s river of news. Google gets a new post on Alzheimer’s or dementia every 7 minutes. That can overwhelm anyone looking for help. This site filters out, focuses on and offers only the best information. it has helped hundreds of thousands of people since it debuted in 2007. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor

Visit Alzheimer's Weekly On

Free:
Alzheimer's & Dementia
Weekly Newsletter

INCLUDES BONUS BOOKLET:
15 Simple Things You Can Do to Care For a Loved One with Dementia or Memory Loss
News, Treatments, Care Tips, Diet, Research, Diagnosis, Therapies & Prevention
News to Get at the Truth

Subscribe To Our Weekly Newsletter

0
Would love your thoughts, please comment.x
()
x